An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer

[1]  J. Berek,et al.  International Journal of Gynecology and Obstetrics Cancer of the Ovary, Fallopian Tube, and Peritoneum , 2022 .

[2]  Xinping Gao,et al.  Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification , 2015, Journal of Ovarian Research.

[3]  B. Monk,et al.  SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. , 2014, Gynecologic oncology.

[4]  R. Arend,et al.  Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? , 2014, World journal of stem cells.

[5]  D. Matei,et al.  Epigenetic targeting of ovarian cancer stem cells. , 2014, Cancer research.

[6]  A. Tinker,et al.  "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit? , 2014, Gynecologic oncology.

[7]  Yigong Shi,et al.  Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models , 2014, Molecular Cancer Therapeutics.

[8]  Y. Li,et al.  Isolation and Characterization of Cancer Stem Cells from High-Grade Serous Ovarian Carcinomas , 2014, Cellular Physiology and Biochemistry.

[9]  C. Morrison,et al.  Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism , 2014, PloS one.

[10]  M. Gore,et al.  Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Silke,et al.  IAP family of cell death and signaling regulators. , 2014, Methods in enzymology.

[12]  D. Saslow,et al.  Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening , 2014, CA: a cancer journal for clinicians.

[13]  A. Rafii,et al.  Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation , 2013, Cell Death and Disease.

[14]  Jenny Chang,et al.  Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. , 2013, Gynecologic oncology.

[15]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[16]  H. Gabra,et al.  Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. , 2013, Cancer treatment reviews.

[17]  M. Pellegrini,et al.  Estrogen and progesterone together expand murine endometrial epithelial progenitor cells , 2013, Stem cells.

[18]  H. Pehamberger,et al.  The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells , 2013, Clinical Cancer Research.

[19]  M. Quinn,et al.  Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance , 2013, Journal of cellular biochemistry.

[20]  R. Buckanovich,et al.  Metformin targets ovarian cancer stem cells in vitro and in vivo. , 2012, Gynecologic oncology.

[21]  S. Memarzadeh,et al.  Stem‐Like Epithelial Cells Are Concentrated in the Distal End of the Fallopian Tube: A Site for Injury and Serous Cancer Initiation , 2012, Stem cells.

[22]  S. Plenchette,et al.  The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular Stress , 2012, Cells.

[23]  D. Vučić,et al.  The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. , 2012, Experimental oncology.

[24]  Gregory A. Wyant,et al.  Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy , 2012, Proceedings of the National Academy of Sciences.

[25]  T. Enomoto,et al.  Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[26]  K. Nephew,et al.  Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide , 2012, Molecular Cancer Therapeutics.

[27]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[28]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[29]  Zhaoyang Wen,et al.  Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). , 2012, Journal of medicinal chemistry.

[30]  Henning Walczak,et al.  No one can whistle a symphony alone – how different ubiquitin linkages cooperate to orchestrate NF-κB activity , 2012, Journal of Cell Science.

[31]  J. Allensworth,et al.  Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism , 2012, Breast Cancer Research and Treatment.

[32]  F. Casagrande,et al.  Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin , 2011, Cancer.

[33]  B. Aggarwal,et al.  NF-κB in cancer: a matter of life and death. , 2011, Cancer discovery.

[34]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[35]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[36]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[37]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[38]  A. Berchuck,et al.  Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. , 2011, Gynecologic oncology.

[39]  B. Neel,et al.  Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells , 2011, Proceedings of the National Academy of Sciences.

[40]  G. Logroscino,et al.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? , 2011, Expert opinion on investigational drugs.

[41]  D. Shah,et al.  Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer , 2011, Cancer Chemotherapy and Pharmacology.

[42]  Robert Brown,et al.  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.

[43]  A. Vlad,et al.  Cancer Management and Research Dovepress Targeted Treatment of Recurrent Platinum-resistant Ovarian Cancer: Current and Emerging Therapies , 2022 .

[44]  S. Memarzadeh,et al.  Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium , 2010, Proceedings of the National Academy of Sciences.

[45]  L. Ricci-Vitiani,et al.  New models for cancer research: human cancer stem cell xenografts. , 2010, Current opinion in pharmacology.

[46]  Tsonwin Hai,et al.  Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. , 2010, Neoplasia.

[47]  A. Sood,et al.  Novel strategies for reversing platinum resistance. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  D. Roberts,et al.  CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.

[49]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[50]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[51]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[52]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[53]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[54]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[55]  R. Hayward.  Stress , 2005, The Lancet.

[56]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[57]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[58]  H. Tomizawa,et al.  Discovery of quinazolines as a novel structural class of potent inhibitors of NF-κB activation , 2003 .

[59]  H. Tomizawa,et al.  Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. , 2003, Bioorganic & medicinal chemistry.

[60]  T. O'brien,et al.  The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences , 2001, Tumor Biology.

[61]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[62]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[63]  A. Eastman,et al.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. , 1990, Biochemical pharmacology.